Wall Street analysts expect Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) to announce earnings of ($0.10) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Ekso Bionics’ earnings. Ekso Bionics reported earnings per share of ($0.41) during the same quarter last year, which would suggest a positive year-over-year growth rate of 75.6%. The company is expected to issue its next earnings results on Tuesday, March 6th.
According to Zacks, analysts expect that Ekso Bionics will report full-year earnings of ($0.81) per share for the current financial year. For the next financial year, analysts expect that the company will post earnings of ($0.35) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that cover Ekso Bionics.
Ekso Bionics (NASDAQ:EKSO) last issued its earnings results on Wednesday, November 8th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05). The business had revenue of $1.60 million for the quarter, compared to the consensus estimate of $2.40 million. Ekso Bionics had a negative return on equity of 323.00% and a negative net margin of 343.53%.
In other Ekso Bionics news, insider Russ Angold sold 50,000 shares of the stock in a transaction dated Wednesday, November 22nd. The shares were sold at an average price of $3.51, for a total transaction of $175,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 3.32% of the stock is owned by company insiders.
Several institutional investors have recently made changes to their positions in EKSO. Carl Domino Inc lifted its holdings in shares of Ekso Bionics by 125.2% in the third quarter. Carl Domino Inc now owns 184,788 shares of the company’s stock worth $224,000 after buying an additional 102,734 shares in the last quarter. Intellectus Partners LLC lifted its holdings in shares of Ekso Bionics by 5.3% in the second quarter. Intellectus Partners LLC now owns 105,294 shares of the company’s stock worth $244,000 after buying an additional 5,294 shares in the last quarter. National Planning Corp lifted its holdings in shares of Ekso Bionics by 122.2% in the third quarter. National Planning Corp now owns 520,942 shares of the company’s stock worth $620,000 after buying an additional 286,492 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Ekso Bionics by 32.9% in the second quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock worth $1,650,000 after buying an additional 176,197 shares in the last quarter. 6.22% of the stock is currently owned by hedge funds and other institutional investors.
Ekso Bionics (NASDAQ:EKSO) opened at $1.80 on Friday. The company has a current ratio of 6.09, a quick ratio of 5.73 and a debt-to-equity ratio of 0.18. The firm has a market cap of $112.62, a PE ratio of -1.94 and a beta of 2.01. Ekso Bionics has a 1 year low of $0.99 and a 1 year high of $4.77.
ILLEGAL ACTIVITY NOTICE: This news story was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://stocknewstimes.com/2018/01/19/brokerages-anticipate-ekso-bionics-holdings-inc-ekso-will-announce-earnings-of-0-10-per-share.html.
About Ekso Bionics
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.